Kanneboyina Nagaraju

Kanneboyina Nagaraju is the Dean of the School of Pharmacy and Pharmaceutical Sciences at the State University of New York (SUNY), Binghamton. He holds the prestigious title of SUNY Distinguished Professor, the highest faculty rank awarded by the State University of New York system.

Nagaraju is a renowned medical scientist and immunologist, known for developing the MHC Class I transgenic mouse model for autoimmune myositis. He played a pivotal role in the identification and development of Vamorolone (AGAMREE), a potent anti-inflammatory and membrane-stabilizing dissociated glucocorticoid with fewer side effects, in collaboration with Eric Hoffman and John McCall. Vamorolone has been approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Healthcare Products Regulatory Agency for the treatment of children with Duchenne Muscular Dystrophy. Additionally, Nagaraju has led global initiatives to improve the rigor and reproducibility of preclinical drug trials and phenotyping in neuromuscular disease models. Provided by Wikipedia